FilingsTodaySeouLinBioscience
At a glance
SeouLinBioscience filed 34 disclosures in the last 12 months, including 4 insider, 2 buyback, 1 5% holder and 1 issuance. The most recent key filing was on Oct 22: Plans to dispose of 9,600 sh of treasury stock, Oct 26 to Oct 30.
Revenue for 2025 was ₩77.1B, up 2.2% on 2024. Operating margin was 0.9% against 1.3% a year earlier. Debt was 38% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩40.3B and operating loss of ₩422.9M.
The 2025 annual report lists 110 employees with an average tenure of 6.9 years and average pay of ₩60.8M, #931 of 1,829 listed companies by average pay. Its 6 directors and auditors were paid ₩289M each on average. It paid ₩100 per common share in cash dividends, against ₩100 a year earlier (+0%). 황을문 and related parties held 28.76% at year end.
From the 2025 annual report
Staff: 110 (70 men, 40 women), of whom 4 on fixed-term contracts. Total pay for the year: ₩6.7B. Directors and auditors: 6, paid ₩1.7B in total.
Dividends (common shares)
| Fiscal year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash dividend per share | ₩100 | ₩100 | ₩100 |
| Payout ratio | 117.8% | 28.9% | -711.3% |
| Yield (as filed) | 1.50% | 1.40% | 1.10% |
| Total cash dividends | ₩862M | ₩843M | ₩836M |
Largest shareholder
황을문 holds 27.36%; with 4 related parties the group holds 28.76% of common shares at year end (from 28.72% at the start of the year).
Individuals paid ₩500M or more
| 황을문 회장 | ₩680M |
| 남찬우 부사장 | ₩527M |
Auditor: 삼덕회계법인 · opinion: Unqualified.
Source: 2025 annual business report (DART). How figures are combined
Financial summary
Key filings
Other filings
Links open the original filing on DART, in Korean.